Maze Therapeutics, Inc.

, in its capacity as administrative agent and collateral agent for itself and the lenders, which provides for a senior secured term loan facility in an aggregate principal amount of up to $ 200.0 million, or the Hercules Term Loan Facility.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

An initial term loan of $ 40.0 million was funded under the Hercules Loan Agreement and the Hercules Term Loan Facility includes up to six additional term loan tranches providing up to an aggregate $ 160.0 million in additional loan commitments through February 2031, so long as the Company satisfies certain conditions precedent.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Historically, the Company has financed its operations primarily through issuances of its equity, issuances of convertible promissory notes, debt financings and license agreements.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Company may seek to raise capital through additional term loan tranches pursuant to the Hercules Term Loan Facility, equity financings, including pursuant to the 2026 Sale Agreement, license agreements, or other sources of financing.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Debt issuance costs and debt discount Debt issuance costs include legal fees, accounting fees and other direct costs incurred in connection with the execution of the Company's debt financings.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Debt discount represents costs paid to the lenders.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

We have entered, and may in the future enter, into strategic collaborations, transactions and licensing partnerships for research, development or commercialization of our programs, including our first therapeutic candidate MZE001, and we may not be able to realize the full value of these partnerships or our partnered programs.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The CODM, in alignment with the Company s overall corporate strategy and goals, analyzes a variety of data to guide segment resource allocation, including program and portfolio scientific data, probability of regulatory and commercial success, and the competitive environment.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Legal Proceedings 29 Item 1A.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

In some cases, you can identify forward-looking statements by terms such as believe, may, will, potentially, estimate, continue, anticipate, intend, could, would, project, plan, expect and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Importantly, this summary does not address all of the risks and uncertainties that we face.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Consequently, you should not consider this summary to be a complete discussion of all potential risks or uncertainties that may substantially impact our business.

SEC original ↗Maze Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026